RAS, wanted dead or alive: Advances in targeting RAS mutant cancers
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
RAS, wanted dead or alive: Advances in targeting RAS mutant cancers
Authors
Keywords
-
Journal
Science Signaling
Volume 13, Issue 624, Pages eaay6013
Publisher
American Association for the Advancement of Science (AAAS)
Online
2020-03-25
DOI
10.1126/scisignal.aay6013
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction
- (2019) Roman C. Hillig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
- (2019) Conan G. Kinsey et al. NATURE MEDICINE
- Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
- (2019) Kirsten L. Bryant et al. NATURE MEDICINE
- Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
- (2019) Marwan Fakih et al. JOURNAL OF CLINICAL ONCOLOGY
- KRASG12C inhibition produces a driver-limited state revealing collateral dependencies
- (2019) Kevin Lou et al. Science Signaling
- Drugging an undruggable pocket on KRAS
- (2019) Dirk Kessler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer
- (2019) Devon R. Blake et al. Science Signaling
- A systems mechanism for KRAS mutant allele–specific responses to targeted therapy
- (2019) Thomas McFall et al. Science Signaling
- Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D
- (2019) Christian W. Johnson et al. Cell Reports
- Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor
- (2018) Matthew R. Janes et al. CELL
- Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
- (2018) Dietrich A. Ruess et al. NATURE MEDICINE
- SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
- (2018) Sara Mainardi et al. NATURE MEDICINE
- Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation
- (2018) Erin Sheffels et al. Science Signaling
- KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism
- (2018) Angelina V. Vaseva et al. CANCER CELL
- KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
- (2018) Sandra Misale et al. CLINICAL CANCER RESEARCH
- The bacterial Ras/Rap1 site-specific endopeptidase RRSP cleaves Ras through an atypical mechanism to disrupt Ras-ERK signaling
- (2018) Marco Biancucci et al. Science Signaling
- Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer
- (2018) Miguel M. Murillo et al. Cell Reports
- RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1
- (2017) S-H Chen et al. ONCOGENE
- Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
- (2017) Chaoyang Sun et al. Science Translational Medicine
- MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance
- (2017) Amy S. Farrell et al. Nature Communications
- Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange
- (2017) Sandrine Guillard et al. Nature Communications
- Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours
- (2016) Andrew Rowland et al. EUROPEAN JOURNAL OF CANCER
- Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring theKRASG13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study
- (2016) Eva Segelov et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of RAS function through targeting an allosteric regulatory site
- (2016) Russell Spencer-Smith et al. Nature Chemical Biology
- The role of wild type RAS isoforms in cancer
- (2016) Bingying Zhou et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes
- (2015) Ana Herrero et al. CANCER CELL
- RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
- (2015) J. Downward CLINICAL CANCER RESEARCH
- Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
- (2015) J. C. Hunter et al. MOLECULAR CANCER RESEARCH
- Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged
- (2014) Paul B. Chapman et al. CANCER CELL
- Wild-Type H- and N-Ras Promote Mutant K-Ras-Driven Tumorigenesis by Modulating the DNA Damage Response
- (2014) Elda Grabocka et al. CANCER CELL
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Functional Redundancy of Sos1 and Sos2 for Lymphopoiesis and Organismal Homeostasis and Survival
- (2013) Fernando C. Baltanás et al. MOLECULAR AND CELLULAR BIOLOGY
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- Tumor adaptation and resistance to RAF inhibitors
- (2013) Piro Lito et al. NATURE MEDICINE
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Tumour maintenance is mediated by eNOS
- (2008) Kian-Huat Lim et al. NATURE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started